{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055608","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.438375+00:00","generated_at":"2026-06-02T09:39:08.972214+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biodesix Q1 revenue $14.8M (+64% YoY); 79% gross margin; raises $55M","bullets":["Total revenue $14.8M (+64% YoY); Lung Diagnostic revenue $13.8M (+60%) on 11,900 test volume (+57%).","Gross margin 79% vs 65% YoY; net loss improved 27% to $13.6M.","Adjusted EBITDA loss $7.0M, improvement of 48% from $13.4M loss in Q1 2023.","Raised $55M gross proceeds in April 2024 oversubscribed offering; cash $11.5M at Q1 end excluding proceeds.","Reaffirmed 2024 revenue guidance of $65M-$68M; new collaboration with MSKCC for cancer diagnostics."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055608","json":"https://secwatch.observer/filing/0000950170-24-055608.json","markdown":"https://secwatch.observer/filing/0000950170-24-055608.md","text":"https://secwatch.observer/filing/0000950170-24-055608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017024055608/0000950170-24-055608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017024055608/bdsx-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:39:08.972214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a9b7d88bb052776596533f8b39765467acc6641","claim":"BIODESIX INC reported the first quarter ended March 31, 2024 results: revenue $14.8 million, net income $13.6 million. Guidance reaffirmed.","evidence_excerpt":"Total revenue of $14.8 million, an increase of 64%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439725/000095017024055608/0000950170-24-055608-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$14.8 million"},{"label":"Net income","value":"$13.6 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}